Harm Reduction Group Valuation
Is NOHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NOHARM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NOHARM's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOHARM?
Key metric: As NOHARM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NOHARM's PS Ratio? | |
|---|---|
| PS Ratio | 0.09x |
| Sales | SEK 162.34m |
| Market Cap | SEK 15.30m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | -1.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NOHARM's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.4x | ||
DUG DUG Foodtech | 6.9x | n/a | SEK 14.2m |
AGTIRA B Agtira | 1.2x | n/a | SEK 38.5m |
UMIDA B Umida Group | 0.7x | n/a | SEK 51.4m |
ARCTIC Arctic Blue Beverages | 0.8x | n/a | SEK 3.7m |
NOHARM Harm Reduction Group | 0.09x | n/a | SEK 15.3m |
Price-To-Sales vs Peers: NOHARM is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.4x).
Price to Sales Ratio vs Industry
How does NOHARM's PS Ratio compare vs other companies in the Global Tobacco Industry?
Price-To-Sales vs Industry: NOHARM is good value based on its Price-To-Sales Ratio (0.1x) compared to the Global Tobacco industry average (2.1x).
Price to Sales Ratio vs Fair Ratio
What is NOHARM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.09x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NOHARM's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.